The risk at specific points in time of additional recognition or reversal of contractual penalties and provisions for losses in connection with the Japan Fair Trade Commission's on-site inspection and continuing investigation into suspected violations of the Antimonopoly Act involving JCHO (Japan Community Health care Organization) prescription-drug tenders.